Literature DB >> 15249500

Protective role for interferon-beta in coxsackievirus B3 infection.

Raj Deonarain1, Dante Cerullo, Koichi Fuse, Peter P Liu, Eleanor N Fish.   

Abstract

BACKGROUND: Coxsackievirus-induced myocarditis can be a serious cause of heart failure. In the absence of a specific antiviral therapy, modulating the host immune response may be protective. Interferons (IFNs)-alpha and -beta perform a fundamental role in innate and adaptive antiviral responses, thereby presenting as candidate therapeutics for coxsackievirus infections. METHODS AND
RESULTS: To examine the contribution of IFN-beta in protection from coxsackievirus B3 (CVB3) infection, mice lacking the IFN-beta gene were infected with 10(3) plaque-forming units of CVB3. In contrast to wild-type mice that exhibit an intact IFN-beta response, we observed increased susceptibility to infection (70% mortality), a downregulation of IFN-stimulated gene targets (2'-5' oligoadenylate synthetase, serine/threonine protein kinase, the GTPase Mx), and cardiomyocyte breakdown and disruption in the IFN-beta-/- mice.
CONCLUSIONS: Viewed together, these results clearly demonstrate that IFN-beta is important in mediating protection against CVB3-induced myocarditis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249500     DOI: 10.1161/01.CIR.0000136824.73458.20

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  64 in total

Review 1.  Immunology in the clinic review series; focus on type 1 diabetes and viruses: the innate immune response to enteroviruses and its possible role in regulating type 1 diabetes.

Authors:  K Lind; M H Hühn; M Flodström-Tullberg
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

2.  Distinct Roles of Interferon Alpha and Beta in Controlling Chikungunya Virus Replication and Modulating Neutrophil-Mediated Inflammation.

Authors:  Lindsey E Cook; Marissa C Locke; Alissa R Young; Kristen Monte; Matthew L Hedberg; Raeann M Shimak; Kathleen C F Sheehan; Deborah J Veis; Michael S Diamond; Deborah J Lenschow
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

Review 3.  Coagulation, protease-activated receptors, and viral myocarditis.

Authors:  Silvio Antoniak; Nigel Mackman
Journal:  J Cardiovasc Transl Res       Date:  2013-11-08       Impact factor: 4.132

Review 4.  Chemical mutagenesis: a new strategy against the global threat of infectious diseases.

Authors:  Etienne Richer; Salman T Qureshi; Silvia M Vidal; Danielle Malo
Journal:  Mamm Genome       Date:  2008-06-17       Impact factor: 2.957

5.  MDA5 and MAVS mediate type I interferon responses to coxsackie B virus.

Authors:  Jennifer P Wang; Anna Cerny; Damon R Asher; Evelyn A Kurt-Jones; Roderick T Bronson; Robert W Finberg
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

Review 6.  Innate and adaptive immune responses against picornaviruses and their counteractions: An overview.

Authors:  Andreas Dotzauer; Leena Kraemer
Journal:  World J Virol       Date:  2012-06-12

7.  Beta interferon regulation of glucose metabolism is PI3K/Akt dependent and important for antiviral activity against coxsackievirus B3.

Authors:  J D Burke; L C Platanias; E N Fish
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

8.  Type III interferons are expressed by Coxsackievirus-infected human primary hepatocytes and regulate hepatocyte permissiveness to infection.

Authors:  K Lind; E Svedin; R Utorova; V M Stone; M Flodström-Tullberg
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

Review 9.  Could interferon-gamma be a therapeutic target for treating heart failure?

Authors:  Scott P Levick; Paul H Goldspink
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

10.  Effects of type I interferons on Friend retrovirus infection.

Authors:  Nicole Gerlach; Simone Schimmer; Siegfried Weiss; Ulrich Kalinke; Ulf Dittmer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.